Navigation Links
Study Finds Widespread Vitamin and Mineral Use Among Cancer Survivors, Although Benefits of Such Use Remain Unclear

SEATTLE, Jan. 31 /PRNewswire/ -- Use of vitamin and mineral supplements among cancer survivors is widespread, despite inconclusive evidence that such use is beneficial, according to a comprehensive review of scientific literature conducted by researchers at Fred Hutchinson Cancer Research Center and published Feb. 1 in the Journal of Clinical Oncology.

"Can vitamin and herbal supplements reduce the adverse effects of cancer treatment, decrease the risk of cancer recurrence or improve a patient's chances of survival? We don't really know. Research into these matters has been minimal," said senior author Cornelia (Neli) Ulrich, Ph.D., an associate member of the Hutchinson Center's Public Health Sciences Division. "While supplement use may be beneficial for some patients, such as those who cannot eat a balanced diet, research suggests that certain supplements may actually interfere with treatment or even accelerate cancer growth," she said.

In reviewing 32 studies conducted between 1999 and 2006, Ulrich and co-author Christine Velicer, Ph.D., formerly a postdoctoral fellow at the Hutchinson Center (now an epidemiologist at Merck Research Laboratory in North Wales, Pa.), found that many of the nation's 10 million adult cancer survivors use nutritional supplements.

They found 64 percent to 81 percent of cancer survivors overall reported using vitamins or minerals (excluding multivitamins), whereas in the general population only 50 percent of adults reported taking dietary supplements.

Survivors of breast cancer reported the highest use (75 percent to 87 percent), whereas prostate-cancer survivors reported the least (26 percent to 35 percent). Factors associated with the highest level of supplement use overall included a higher level of education and being female.

The researchers also found that many people initiate the use of vitamins and supplements after cancer diagnosis; between 14 percent and 32 percent start taking them after learning they have cancer.

"Cancer survivors report that they hope to strengthen their immune system with supplement use or gain a sense of control and empowerment," Ulrich said. However, many cancer survivors who use supplements do not let their doctors know; 31 percent to 68 percent of cancer patients and survivors who use supplements may not disclose this information or their doctors may fail to record it in their charts.

"This is disconcerting and suggests that many physicians may not recognize the importance of understanding whether their patients are taking supplements," Ulrich said.

Knowing about supplement use is crucial, she continues, because of potential adverse effects. "Evidence clearly suggests the need for caution," Ulrich said. "Some vitamins, such as folic acid, may be involved in cancer progression while others, such as St. John's wort, can interfere with chemotherapy. However, we really need more research to understand whether use of these supplements can be beneficial or do more harm than good."

Until research clarifies the effects of vitamin use in cancer survivors, the authors urge health care professionals to communicate openly with their patients about supplement use. "A simple explanation that medical studies show supplement use may not always be beneficial may help cancer survivors make well-informed decisions," the authors wrote.

The National Cancer Institute funded this research.

At Fred Hutchinson Cancer Research Center, our interdisciplinary teams of world-renowned scientists and humanitarians work together to prevent, diagnose and treat cancer, HIV/AIDS and other diseases. Our researchers, including three Nobel laureates, bring a relentless pursuit and passion for health, knowledge and hope to their work and to the world. For more information, please visit


Kristen Woodward

(206) 667-5095

SOURCE Fred Hutchinson Cancer Research Center
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. The LANCET Published ENDORSE, the Largest Multinational Study Showing That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE Prophylaxis
2. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
3. Venture Capitalists Bullish on Greentech and Biotech, KPMG Study Says
4. Study Shows Coronado Biosciences Bcl-2 Inhibitor, Apogossypol, is More Efficacious, Less Toxic than Gossypol in Animal Models
5. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
6. Kaiser Permanente Study Shows Newer, Stronger Evidence That Caffeine During Pregnancy Increases Miscarriage Risk
7. Center for Molecular Medicine Selected to Provide DNA Analysis for Childrens Oncology Group Leukemia Study
8. Phase I Safety and Tolerability Study With EVT 302 Successfully Completed
9. Study Examines Media Preferences of Life Scientists in Applied Markets
10. Triage study challenges notions of emergency medical response to disaster
11. Federally-Funded Study Shows More Women Can Avoid Hysterectomy for Common Problem
Post Your Comments:
(Date:10/11/2017)... ... October 11, 2017 , ... Singh ... orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of ... SBT-100 is able to cross the cell membrane and bind intracellular STAT3 and ...
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... ... Science Center’s FirstHand program has won a US2020 STEM Mentoring Award. Representatives of ... award for Excellence in Volunteer Experience from US2020. , US2020’s mission is to ...
(Date:10/10/2017)... SANTA CRUZ, Calif. , Oct. 10, 2017 /PRNewswire/ ... SBIR grant from the NIH to develop RealSeq®-SC (Single ... preparation kit for profiling small RNAs (including microRNAs) from ... Cell Analysis Program highlights the need to accelerate development ... "New techniques for ...
(Date:10/9/2017)... Oct. 9, 2017  BioTech Holdings announced today ... which its ProCell stem cell therapy prevents limb ... The Company, demonstrated that treatment with ProCell resulted ... saved as compared to standard bone marrow stem ... resulted in reduction of therapeutic effect.  ...
Breaking Biology Technology:
(Date:5/16/2017)... May 16, 2017  Veratad Technologies, LLC ( ... age and identity verification solutions, announced today they will ... 2017, May 15 thru May 17, 2017, in ... International Trade Center. Identity impacts the ... in today,s quickly evolving digital world, defining identity is ...
(Date:4/18/2017)... Inc., a global expert in SoC-based imaging and computing solutions, has ... features the company,s hybrid codec technology. A demonstration utilizing TeraFaces ® ... be showcased during the upcoming Medtec Japan at Tokyo Big Sight ... Las Vegas Convention Center April 24-27. ... Click here for an image of the ...
(Date:4/11/2017)... Apr. 11, 2017 Research and Markets has ... report to their offering. ... The global eye tracking market to grow at a CAGR of ... Eye Tracking Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. The ...
Breaking Biology News(10 mins):